LGALS3 and Myocardial fibrosis: These results imply that Gal-3 is a viable biomarker for subclinical CVD as it combines inflammatory and fibrotic pathways [23]. Galectin-3 may guide decisions regarding cardiac imaging or intensification of immunosuppression in patients with suspected myocardial fibrosis.